346P - A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treat...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Central Nervous System Malignancies
Presenter eleonora Bergo
Citation Annals of Oncology (2016) 27 (6): 103-113. 10.1093/annonc/mdw367
Authors E. Bergo1, G. Lombardi1, P. Del Bianco2, F. Berti3, L. Bellu1, A. Pambuku1, V. Zagonel1
  • 1Department Of Clinical And Experimental Oncology, Medical Oncology 1, Veneto Institute of Oncology - IRCCS, 35100 - Padova/IT
  • 2Clinical Trials And Biostatistics Unit, And Molecular Immunology And Oncology Unit, Veneto Institute of Oncology - IRCCS, 35128 - Padova/IT
  • 3Radiation Therapy And Nuclear Medicine Unit, Veneto Institute of Oncology - IRCCS, 35100 - Padova/IT

Abstract

Background

GBM PTS can show changes in CF during the treatment which can affect their daily lives. We analyzed QoL, PSY and CF in these PTS treated with RT plus TMZ.

Methods

PTS with newly histologically diagnosed GBM treated with RT and TMZ as first-line therapy and KPS ≥ 60 were enrolled. We assessed QoL using EORTC QLQ-C30 and BN20. CF were evaluated with MMSE, and PSY with HADS test. Evaluations were performed at each radiological assessment: T0 (before treatment), T1 (1 month after RT + TMZ), T2 (6 ms from T0), T3 (9 ms from T0) and T4 (12 ms from T0). A repeated-measure linear mixed-model was used to estimate group differences over time and χ2 test for compare mean values at each time.

Results

we enrolled 112 PTS, median age was 59; 69 PTS were male and 36 PTS aged ≥65. All PTS were treated with TMZ until disease progression. Role functioning (RF) statistically improved over time in female (p = 0.02) and PTS

Conclusions

Some variables related to QoL, PSY and CF may improve during standard treatment with RT and TMZ in PTS with GBM. Moreover, age, gender and site of lesion might impact on specific factors. Radiological progression may correlate with worsening of specific points for QoL, PSY and CF.

Clinical trial identification

Legal entity responsible for the study

IOV

Funding

None

Disclosure

All authors have declared no conflicts of interest.